{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:32:33Z","timestamp":1793082753181,"version":"4.5.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. The current treatment standards include complete surgical resection for localized resectable disease and systemic therapy with mitotane alone or in combination with etoposide, doxorubicin, and cisplatin in patients with advanced ACC. However, the efficacy of systemic therapy in ACC is very limited, with high rates of toxicities. The understanding of altered molecular pathways is critically important to identify effective treatment options that currently do not exist. In this review, we discuss the results of recent advanced in molecular profiling of ACC with the focus on dysregulated pathways from various genomic and epigenetic dysregulation. We discuss the potential translational therapeutic implication of molecular alterations. In addition, we review and summarize the results of recent clinical trials and ongoing trials.<\/jats:p>","DOI":"10.3389\/fendo.2021.613248","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T06:03:42Z","timestamp":1614578622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Current Status and Future Targeted Therapy in Adrenocortical Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"George","family":"Alyateem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naris","family":"Nilubol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0022-5347(05)64023-2","article-title":"Adrenocortical carcinoma: diagnosis, evaluation and treatment","volume":"169","author":"Ng","year":"2003","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3503w","article-title":"The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population Based Study","volume":"10","author":"Sharma","year":"2018","journal-title":"J Clin Med Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2017.18.10.2817","article-title":"Prognostic Factors of Adrenocortical Carcinoma: An Analysis of theSurveillance Epidemiology and End Results (SEER) Database","volume":"18","author":"Wang","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-001-0047-y","article-title":"Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group","volume":"25","author":"Icard","year":"2001","journal-title":"World J Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J Clin Endocr Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24439","article-title":"Actual 10-year survivors following resection of adrenocortical carcinoma","volume":"114","author":"Tran","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-999-0719-7","article-title":"Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma","volume":"6","author":"Schulick","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0803","article-title":"Improved survival in patients with stage II adrenocortical carcinomafollowed up prospectively by specialized centers","volume":"95","author":"Fassnacht","year":"2010","journal-title":"J Clin EndocrinolMetab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2559","article-title":"The role of surgery in the management of recurrent adrenocortical carcinoma","volume":"98","author":"Erdogan","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2358-7","article-title":"Resection of adrenocortical carcinoma liver metastasis: is it justified","volume":"19","author":"Gaujoux","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2011.05.013","article-title":"Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience","volume":"92","author":"Kemp","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2007.09.006","article-title":"Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma","author":"Gonzalez","year":"2007","journal-title":"Surgery Discussion"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocorticalcarcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.6863","article-title":"Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children\u2019s oncology group study","volume":"33","author":"Wasserman","year":"2015","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2198","article-title":"Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma","volume":"98","author":"Raymond","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1982","article-title":"TP53 germline mutations in adult patients with adrenocortical carcinoma","volume":"97","author":"Herrmann","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.8.606","article-title":"Multiple primary cancers in families with Li-Fraumeni syndrome","volume":"90","author":"Hisada","year":"1998","journal-title":"Jnci-J Natl Cancer I"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ejhg.2009.106","article-title":"Beckwith-Wiedemann syndrome","volume":"18","author":"Weksberg","year":"2010","journal-title":"Eur J Hum Genet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(05)80117-5","article-title":"Adrenal lesion in multiple endocrine neoplasia type 1","volume":"118","author":"Skogseid","year":"1995","journal-title":"Surgery"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0679","article-title":"Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d\u2019etude des Tumeurs Endocrines database","volume":"166","author":"Gatta-Cherifi","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.10.006","article-title":"Pathogenesis of adrenocortical cancer","volume":"23","author":"Bertherat","year":"2009","journal-title":"Best Pract Res Cl En"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2321","article-title":"Carney complex with adrenal cortical carcinoma","volume":"97","author":"Morin","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2244","article-title":"A Large Family with Carney Complex Caused by the S147G PRKAR1A Mutation Shows a Unique Spectrum of Disease Including Adrenocortical Cancer","volume":"97","author":"Anselmo","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie","year":"2014","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.6.1444","article-title":"Rearrangements at the 11p15 Locus and Overexpression of Insulin-Like Growth Factor-Ii Gene in Sporadic Adrenocortical Tumors","volume":"78","author":"Gicquel","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for newcancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26050","article-title":"Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response","volume":"9","author":"Nilubol","year":"2018","journal-title":"Oncotarget"},{"key":"B40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/1471-2105-9-365","article-title":"Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions","volume":"9","author":"Houseman","year":"2008","journal-title":"BMC Bioinf"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2993","article-title":"Identification of a CpG island methylator phenotype in adrenocortical carcinomas","volume":"98","author":"Barreau","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1587","article-title":"miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer","volume":"15","author":"Soon","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25724","article-title":"MicroRNA Profiling of Adrenocortical Tumors Reveals miR-483 as a Marker of Malignancy","volume":"117","author":"Patterson","year":"2011","journal-title":"Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0051","article-title":"Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients","volume":"20","author":"Chabre","year":"2013","journal-title":"Endocrine-Related Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12030724","article-title":"Early Postoperative Circulating miR-483-5p Is a Prognosis Marker forAdrenocortical Cancer","volume":"12","author":"Oreglia","year":"2020","journal-title":"Cancers"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival","volume":"27","author":"de Reynies","year":"2009","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/ng1449","article-title":"Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B","volume":"36","author":"Hanks","year":"2004","journal-title":"Nat Genet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.1096284","article-title":"Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw136","article-title":"EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression","volume":"25","author":"Drelon","year":"2016","journal-title":"Hum Mol Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocyteson the prognosis of adrenocortical carcinoma","volume":"8","author":"Landwehr","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0452","article-title":"Future directions in the diagnosis and medical treatment of adrenocortical carcinoma","volume":"23","author":"Creemers","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma - towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1270-0","article-title":"Palbociclib inhibits proliferation of human adrenocortical tumor cells","volume":"59","author":"Fiorentini","year":"2018","journal-title":"Endocrine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101356","article-title":"A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas","volume":"9","author":"Hadjadj","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume-title":"JCO Precis Oncol","author":"Chakravarty","year":"2017"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2256","article-title":"Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma","volume":"22","author":"Satoh","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-10-198","article-title":"Four clinically utilized drugs were identified and validated fortreatment of adrenocortical cancer using quantitative high-throughput screening","volume":"10","author":"Nilubol","year":"2012","journal-title":"J Trans Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2671","article-title":"Quantitative High-Throughput Drug Screening Identifies Novel Classes of Drugs with Anticancer Activity in Thyroid Cancer Cells: Opportunities for Repurposing","volume":"97","author":"Zhang","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206863","article-title":"Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK\/JNK- and NF-kappaB-dependent process","volume":"22","author":"Dai","year":"2003","journal-title":"Oncogene"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/science.1257216","article-title":"Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors","volume":"347","author":"Flynn","year":"2015","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"328ra328","DOI":"10.1126\/scitranslmed.aac8228","article-title":"ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma","volume":"8","author":"Koschmann","year":"2016","journal-title":"Sci Trans Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Josse","year":"2014","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I Study of ATR Inhibitor M6620 in Combination With Topotecanin Patients With Advanced Solid Tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"New Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-RepairDeficiency","volume":"372","author":"Le","year":"2015","journal-title":"New Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0163","article-title":"Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome","volume":"22","author":"Ronchi","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2371","article-title":"Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma","volume":"18","author":"Simon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1780","article-title":"Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials","volume":"25","author":"Tuxen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.54","article-title":"P53\/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model","volume":"36","author":"Batisse-Lignier","year":"2017","journal-title":"Oncogene"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.1315","article-title":"Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines","volume":"15","author":"Cerquetti","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11111768","article-title":"Antineoplastic Effect of a Combined Mitotane Treatment\/IonizingRadiation in Adrenocortical Carcinoma: A Preclinical Study","volume":"11","author":"Cerquetti","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006741","article-title":"The efficacy of radiation therapy in adrenocortical carcinoma: A propensity score analysis of a population-based study","volume":"96","author":"Luo","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24331","article-title":"Radiotherapy in adrenocortical carcinoma","volume":"115","author":"Polat","year":"2009","journal-title":"Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11084","article-title":"Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases","volume":"97","author":"Wood","year":"2003","journal-title":"Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz091","article-title":"Treatment With 90Y\/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors","volume":"105","author":"Grisanti","year":"2020","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.613248\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T06:03:45Z","timestamp":1614578625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.613248\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":83,"alternative-id":["10.3389\/fendo.2021.613248"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.613248","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"article-number":"613248"}}